Logo image of SNDX

SYNDAX PHARMACEUTICALS INC (SNDX) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:SNDX - US87164F1057 - Common Stock

18.79 USD
-0.33 (-1.73%)
Last: 12/2/2025, 8:07:33 PM
18.73 USD
-0.06 (-0.32%)
After Hours: 12/2/2025, 8:07:33 PM
Fundamental Rating

3

Overall SNDX gets a fundamental rating of 3 out of 10. We evaluated SNDX against 534 industry peers in the Biotechnology industry. SNDX may be in some trouble as it scores bad on both profitability and health. SNDX is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year SNDX has reported negative net income.
In the past year SNDX has reported a negative cash flow from operations.
SNDX had negative earnings in 4 of the past 5 years.
SNDX had negative operating cash flow in 4 of the past 5 years.
SNDX Yearly Net Income VS EBIT VS OCF VS FCFSNDX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100M -200M -300M

1.2 Ratios

SNDX has a Return On Assets (-56.44%) which is in line with its industry peers.
With a Return On Equity value of -269.78%, SNDX is not doing good in the industry: 70.22% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -56.44%
ROE -269.78%
ROIC N/A
ROA(3y)-36.06%
ROA(5y)-25.66%
ROE(3y)-60.12%
ROE(5y)-40.97%
ROIC(3y)N/A
ROIC(5y)N/A
SNDX Yearly ROA, ROE, ROICSNDX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100 -150

1.3 Margins

SNDX has a Gross Margin of 95.44%. This is amongst the best in the industry. SNDX outperforms 95.13% of its industry peers.
SNDX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 95.44%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SNDX Yearly Profit, Operating, Gross MarginsSNDX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5K -10K -15K

More info and screens

3

2. Health

2.1 Basic Checks

SNDX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for SNDX has been increased compared to 1 year ago.
The number of shares outstanding for SNDX has been increased compared to 5 years ago.
SNDX has a worse debt/assets ratio than last year.
SNDX Yearly Shares OutstandingSNDX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
SNDX Yearly Total Debt VS Total AssetsSNDX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

SNDX has an Altman-Z score of -2.09. This is a bad value and indicates that SNDX is not financially healthy and even has some risk of bankruptcy.
SNDX's Altman-Z score of -2.09 is in line compared to the rest of the industry. SNDX outperforms 51.12% of its industry peers.
SNDX has a Debt/Equity ratio of 2.78. This is a high value indicating a heavy dependency on external financing.
With a Debt to Equity ratio value of 2.78, SNDX is not doing good in the industry: 80.71% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 2.78
Debt/FCF N/A
Altman-Z -2.09
ROIC/WACCN/A
WACC8.43%
SNDX Yearly LT Debt VS Equity VS FCFSNDX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

2.3 Liquidity

SNDX has a Current Ratio of 4.64. This indicates that SNDX is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 4.64, SNDX is in line with its industry, outperforming 53.37% of the companies in the same industry.
A Quick Ratio of 4.42 indicates that SNDX has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 4.42, SNDX is in line with its industry, outperforming 52.62% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.64
Quick Ratio 4.42
SNDX Yearly Current Assets VS Current LiabilitesSNDX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

7

3. Growth

3.1 Past

SNDX shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 0.55%.
Looking at the last year, SNDX shows a very strong growth in Revenue. The Revenue has grown by 597.19%.
The Revenue has been growing by 73.64% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)0.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%28.57%
Revenue 1Y (TTM)597.19%
Revenue growth 3Y-44.66%
Revenue growth 5Y73.64%
Sales Q2Q%266.97%

3.2 Future

SNDX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 21.57% yearly.
The Revenue is expected to grow by 57.94% on average over the next years. This is a very strong growth
EPS Next Y14.48%
EPS Next 2Y24.61%
EPS Next 3Y24.01%
EPS Next 5Y21.57%
Revenue Next Year77.13%
Revenue Next 2Y95.13%
Revenue Next 3Y74.29%
Revenue Next 5Y57.94%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
SNDX Yearly Revenue VS EstimatesSNDX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
SNDX Yearly EPS VS EstimatesSNDX Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4 -4 6

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

SNDX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year SNDX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SNDX Price Earnings VS Forward Price EarningsSNDX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SNDX Per share dataSNDX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2 -3

4.3 Compensation for Growth

SNDX's earnings are expected to grow with 24.01% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.61%
EPS Next 3Y24.01%

More info and screens

0

5. Dividend

5.1 Amount

SNDX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SYNDAX PHARMACEUTICALS INC

NASDAQ:SNDX (12/2/2025, 8:07:33 PM)

After market: 18.73 -0.06 (-0.32%)

18.79

-0.33 (-1.73%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-03 2025-11-03/amc
Earnings (Next)03-02 2026-03-02/amc
Inst Owners120.99%
Inst Owner Change-1.6%
Ins Owners1.13%
Ins Owner Change-0.23%
Market Cap1.63B
Revenue(TTM)111.55M
Net Income(TTM)-311.41M
Analysts87
Price Target39.07 (107.93%)
Short Float %29.87%
Short Ratio8.77
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)12.08%
Min EPS beat(2)4.24%
Max EPS beat(2)19.92%
EPS beat(4)3
Avg EPS beat(4)-79.67%
Min EPS beat(4)-370.62%
Max EPS beat(4)27.8%
EPS beat(8)7
Avg EPS beat(8)-34.32%
EPS beat(12)11
Avg EPS beat(12)-20.09%
EPS beat(16)15
Avg EPS beat(16)19.64%
Revenue beat(2)1
Avg Revenue beat(2)16.23%
Min Revenue beat(2)-6.26%
Max Revenue beat(2)38.73%
Revenue beat(4)2
Avg Revenue beat(4)-5.66%
Min Revenue beat(4)-91.24%
Max Revenue beat(4)38.73%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-0.28%
PT rev (3m)2.53%
EPS NQ rev (1m)6.81%
EPS NQ rev (3m)11.68%
EPS NY rev (1m)0.59%
EPS NY rev (3m)2.64%
Revenue NQ rev (1m)-0.95%
Revenue NQ rev (3m)2.89%
Revenue NY rev (1m)0.92%
Revenue NY rev (3m)7.42%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 14.64
P/FCF N/A
P/OCF N/A
P/B 14.15
P/tB 14.15
EV/EBITDA N/A
EPS(TTM)-3.61
EYN/A
EPS(NY)-1.67
Fwd EYN/A
FCF(TTM)-3.57
FCFYN/A
OCF(TTM)-3.57
OCFYN/A
SpS1.28
BVpS1.33
TBVpS1.33
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -56.44%
ROE -269.78%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 95.44%
FCFM N/A
ROA(3y)-36.06%
ROA(5y)-25.66%
ROE(3y)-60.12%
ROE(5y)-40.97%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.2
Health
Industry RankSector Rank
Debt/Equity 2.78
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.64
Quick Ratio 4.42
Altman-Z -2.09
F-Score4
WACC8.43%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)0.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%28.57%
EPS Next Y14.48%
EPS Next 2Y24.61%
EPS Next 3Y24.01%
EPS Next 5Y21.57%
Revenue 1Y (TTM)597.19%
Revenue growth 3Y-44.66%
Revenue growth 5Y73.64%
Sales Q2Q%266.97%
Revenue Next Year77.13%
Revenue Next 2Y95.13%
Revenue Next 3Y74.29%
Revenue Next 5Y57.94%
EBIT growth 1Y4.71%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year1.28%
EBIT Next 3Y25.42%
EBIT Next 5YN/A
FCF growth 1Y-118.52%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-118.43%
OCF growth 3YN/A
OCF growth 5YN/A

SYNDAX PHARMACEUTICALS INC / SNDX FAQ

What is the ChartMill fundamental rating of SYNDAX PHARMACEUTICALS INC (SNDX) stock?

ChartMill assigns a fundamental rating of 3 / 10 to SNDX.


What is the valuation status of SYNDAX PHARMACEUTICALS INC (SNDX) stock?

ChartMill assigns a valuation rating of 1 / 10 to SYNDAX PHARMACEUTICALS INC (SNDX). This can be considered as Overvalued.


Can you provide the profitability details for SYNDAX PHARMACEUTICALS INC?

SYNDAX PHARMACEUTICALS INC (SNDX) has a profitability rating of 1 / 10.


Can you provide the financial health for SNDX stock?

The financial health rating of SYNDAX PHARMACEUTICALS INC (SNDX) is 3 / 10.


What is the earnings growth outlook for SYNDAX PHARMACEUTICALS INC?

The Earnings per Share (EPS) of SYNDAX PHARMACEUTICALS INC (SNDX) is expected to grow by 14.48% in the next year.